Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 1,951 Shares

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 1,951 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $255,893.16. Following the completion of the transaction, the director owned 11,048 shares in the company, valued at approximately $1,449,055.68. This trade represents a 15.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Tuesday, June 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $130.19, for a total transaction of $15,102.04.
• On Monday, May 18th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $95.96, for a total transaction of $11,131.36.
• On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $84.83, for a total transaction of $9,840.28.

Guardant Health Trading Up 1.6%

Shares of NASDAQ:GH traded up $2.00 during trading on Tuesday, reaching $130.83. The company had a trading volume of 1,931,570 shares, compared to its average volume of 2,130,785. The company has a fifty day moving average of $108.07 and a two-hundred day moving average of $103.04. The stock has a market capitalization of $17.35 billion, a P/E ratio of -38.59 and a beta of 1.61. Guardant Health, Inc. has a 12 month low of $40.35 and a 12 month high of $135.00.

Institutional Trading of Guardant Health

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Guardant Health by 2.1% in the fourth quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock worth $1,242,101,000 after buying an additional 251,939 shares during the period. Price T Rowe Associates Inc. MD grew its position in Guardant Health by 33.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after acquiring an additional 1,414,441 shares during the last quarter. Franklin Resources Inc. increased its stake in Guardant Health by 14.9% in the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock worth $343,348,000 after purchasing an additional 435,232 shares during the period. Geode Capital Management LLC increased its stake in Guardant Health by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock worth $328,297,000 after purchasing an additional 277,001 shares during the period. Finally, Fuller & Thaler Asset Management Inc. lifted its position in Guardant Health by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after purchasing an additional 72,162 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on GH shares. BTIG Research set a $160.00 price target on Guardant Health and gave the stock a “buy” rating in a research note on Wednesday, May 27th. Guggenheim lowered Guardant Health from a “buy” rating to a “buy” rating in a research report on Thursday, May 28th. Wolfe Research assumed coverage on Guardant Health in a report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price objective on the stock. Mizuho boosted their target price on Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Finally, Royal Bank Of Canada started coverage on Guardant Health in a research report on Thursday, June 11th. They issued an “outperform” rating and a $185.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Guardant Health currently has an average rating of “Moderate Buy” and a consensus price target of $141.95.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.